Comparative Outcomes of First-Line Chemotherapy for Metastatic Pancreatic Cancer Among the Regimens Used in Japan
Sign Up to like & getrecommendations! Published in 2022 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2021.45515
Abstract: Key Points Question What are the comparative short-term and long-term outcomes associated with first-line chemotherapy regimens for patients with metastatic pancreatic cancer, and how do they compare with chemotherapy regimens recommended in Japanese guidelines? Findings… read more here.
Keywords: metastatic pancreatic; pancreatic cancer; first line; line chemotherapy ... See more keywords
Comparison of FOLFIRINOX vs Gemcitabine Plus Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma
Sign Up to like & getrecommendations! Published in 2022 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2022.16199
Abstract: Key Points Question Is there a difference in survival or toxic effects between the main first-line therapies used for metastatic pancreatic cancer? Findings In this comparative effectiveness study that included 1102 patients, FOLFIRINOX (combined leucovorin… read more here.
Keywords: gemcitabine plus; metastatic pancreatic; plus nab; first line ... See more keywords
Association of Antibiotic Receipt With Survival Among Patients With Metastatic Pancreatic Ductal Adenocarcinoma Receiving Chemotherapy
Sign Up to like & getrecommendations! Published in 2023 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2023.4254
Abstract: Key Points Question Is antibiotic therapy associated with response to chemotherapy in patients with metastatic pancreatic ductal adenocarcinoma (PDAC)? Findings In this cohort study of 3850 older adults with metastatic PDAC, receipt of perichemotherapy antibiotics… read more here.
Keywords: metastatic pancreatic; ductal adenocarcinoma; survival among; pancreatic ductal ... See more keywords
Reducing nihilism in metastatic pancreatic ductal adenocarcinoma: Treatment, sequencing, and effects on survival outcomes
Sign Up to like & getrecommendations! Published in 2020 at "Cancer Medicine"
DOI: 10.1002/cam4.3477
Abstract: Real‐world practice patterns, treatment sequencing, and outcomes in patients with metastatic pancreatic cancer remain unclear. Previous research indicates that the likelihood of patients with metastatic pancreatic cancer receiving or continuing cancer‐directed therapy is low—a phenomenon… read more here.
Keywords: metastatic pancreatic; treatment; treatment sequencing; pancreatic ductal ... See more keywords
Patient‐centered outcomes in the POLO study of active maintenance olaparib for germline BRCA‐mutated metastatic pancreatic cancer
Sign Up to like & getrecommendations! Published in 2023 at "Cancer"
DOI: 10.1002/cncr.34610
Abstract: The phase 3 POLO study demonstrated a significant progression‐free survival (PFS) benefit and preserved health‐related quality of life (HRQOL) for active maintenance treatment with olaparib vs placebo in patients with metastatic pancreatic cancer and a… read more here.
Keywords: metastatic pancreatic; germline brca; pancreatic cancer; active maintenance ... See more keywords
Analysis of ctDNA to predict prognosis and monitor treatment responses in metastatic pancreatic cancer patients
Sign Up to like & getrecommendations! Published in 2017 at "International Journal of Cancer"
DOI: 10.1002/ijc.30650
Abstract: Cell‐free circulating tumor DNA (ctDNA) in plasma has been used as a potential noninvasive biomarker for various tumors. Our study was performed to evaluate the clinical implications of ctDNA detection in patients with metastatic pancreatic… read more here.
Keywords: metastatic pancreatic; ctdna; treatment; pancreatic cancer ... See more keywords
Gemcitabine Combined with the mTOR Inhibitor Temsirolimus in Patients with Locally Advanced or Metastatic Pancreatic Cancer. A Hellenic Cooperative Oncology Group Phase I/II Study
Sign Up to like & getrecommendations! Published in 2018 at "Targeted Oncology"
DOI: 10.1007/s11523-018-0605-y
Abstract: BackgroundThe prognosis of patients with advanced pancreatic cancer is dismal, and there is a need for novel and effective treatments.ObjectivesTο determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs) of a novel gemcitabine (G)… read more here.
Keywords: phase; metastatic pancreatic; pancreatic cancer; patients locally ... See more keywords
Systemic Therapies for Metastatic Pancreatic Neuroendocrine Tumors
Sign Up to like & getrecommendations! Published in 2019 at "Current Treatment Options in Oncology"
DOI: 10.1007/s11864-019-0690-x
Abstract: Over the years, there have been significant advances in systemic treatments for metastatic pancreatic neuroendocrine tumors (panNETs). Despite these advancements, uncertainty remains regarding how to best sequence available therapies. For well-differentiated and metastatic panNETs that… read more here.
Keywords: systemic therapies; metastatic pancreatic; therapies metastatic; pancreatic neuroendocrine ... See more keywords
Treatment landscape of metastatic pancreatic cancer.
Sign Up to like & getrecommendations! Published in 2021 at "Cancer treatment reviews"
DOI: 10.1016/j.ctrv.2021.102180
Abstract: Pancreatic ductal adenocarcinoma (PDAC) is an aggressive form of cancer with a dismal prognosis. The lack of symptoms in the early phase of the disease makes early diagnosis challenging, and about 80-85% of the patients… read more here.
Keywords: metastatic pancreatic; treatment landscape; line; treatment ... See more keywords
NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors.
Sign Up to like & getrecommendations! Published in 2019 at "European journal of cancer"
DOI: 10.1016/j.ejca.2018.12.007
Abstract: BACKGROUND Liposomal irinotecan (nal-IRI) plus 5-fluorouracil and leucovorin (5-FU/LV) is approved for patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy. This approval was based on significantly improved median overall survival compared… read more here.
Keywords: nal iri; long term; overall survival; metastatic pancreatic ... See more keywords
Anti-EGFR chimeric antigen receptor-modified T cells in metastatic pancreatic carcinoma: A phase I clinical trial.
Sign Up to like & getrecommendations! Published in 2020 at "Cytotherapy"
DOI: 10.1016/j.jcyt.2020.04.088
Abstract: The current clinical outcome for patients with metastatic pancreatic carcinoma (PC) remains poor. Epidermal growth factor receptor (EGFR) is detectable in PC, suggesting that EGFR is a rational target in PC. We conducted a phase… read more here.
Keywords: egfr; metastatic pancreatic; trial; pancreatic carcinoma ... See more keywords